Aoife Brennan/LinkedIn
Jun 12, 2026, 14:27
Aoife Brennan: Ongoing Budo Study Demonstrates Potential in Challenging ITP Population
Aoife Brennan, Board Member at Critical Path Institute (C-Path), President and CEO of Climb Bio, shared a post on LinkedIn:
“Delighted to share data from our ongoing study of budo in ITP today at EHA.
Many of the patients enrolled had a higher number of prior lines of therapy than baseline platelet count which illustrates the need for new treatments that provide durable treatment response.
Immense gratitude to the patients and investigators who are participating and congratulations to the team Climb Bio.”
Stay updated with Hemostasis Today.
-
Jun 15, 2026, 18:24Celebrating Emna Gouider’s Renewed Leadership at WFH Congress 2026 – WFH
-
Jun 15, 2026, 18:14Anastasia Conti: Connecting Celebrating and Advancing Hematology at EHA 2026
-
Jun 15, 2026, 18:01Eric Mwenda: Honoring Blood Donors and Partnerships in Tanzania
-
Jun 15, 2026, 17:37Vincent Elsey: The Ethereal Anatomy of a Broken Vessel
-
Jun 15, 2026, 17:20Megan Adediran: Small Act, Massive Impact – Celebrating Blood Donor Day
-
Jun 15, 2026, 16:52Alejandro González Veliz: A Modern Approach to Anticoagulant Management
-
Jun 15, 2026, 16:20New Therapeutic Strategies Targeting Iron Metabolism
-
Jun 15, 2026, 15:43Antonio Paul: Donor Safety Is More Than a Sterile Needle
-
Jun 15, 2026, 15:36Alejandro González Veliz: A Coronary Calcium Score of Zero Doesn’t Always Mean Zero Risk